AstraZenica CEO quits after drug sales slump

Quote of the day: 'After more than six years as chief executive officer of this great company I have decided that now is the right time to step down and allow a new leader to take the reins.' David Brennan has abruptly quit as AstraZenica chief exec after investors voiced their discontent in a boardroom coup. Underlying profits at the drug-maker fell 19% in the first quarter of 2012, causing the share price to drop by 3.5% this morning. Brennan's shock departure has forced the board to scramble for an interim CEO; chief financial officer Simon Lowth is stepping into the breach while a permanent successor is found.

by Rebecca Burn-Callander
Last Updated: 09 Oct 2013
.

Find this article useful?

Get more great articles like this in your inbox every lunchtime

How not to handle redundancies

It can come back to bite you if you get it wrong.

Sarah Willingham: I will never start another business again

The entrepreneur and investor on top leadership skills, pivotal career moments and Dragons' Den.

A new etiquette for video meetings

Virtual calls are not the same as in-person conversations, so we need to change the...

There's opportunity in this recession

A Schumpeterian view of closing businesses.

Is it okay to spy on my staff if I think they're slacking ...

Everything you wanted to know about employee surveillance but were afraid to ask.

The psychology of remote working

In depth: The lockdown has proven that we can make working from home work, but...